BPC-157 is a synthetic 15-amino-acid peptide. A rat pharmacokinetic study reported rapid plasma clearance after subcutaneous administration. Human half-life, bioavailability, efficacy, effect duration, and an appropriate human schedule remain unknown.
BPC-157: Halflife Labs records ~15 min plasma (rat) for SC / Oral / IM. Evidence classification: Preclinical, inferred, community, or unresolved source. Source summary: Xu et al., Front Pharmacol 2022, PMC9794587.
Limitation: This value is estimated, inferred, or derived from nonhuman or lower-confidence evidence and cannot be assumed to apply to an individual human. Scientific review is documented on this page; the limited reviewer scope is defined on the About page.
Stable record ID: hlc:bpc-157 · Page revision: 2026-06-11 · Open the primary source
The human half-life of BPC-157 is unknown. The approximately 15-minute figure comes from a rat pharmacokinetic study and cannot be assumed to describe human exposure. No FDA-approved BPC-157 product exists, and FDA has identified BPC-157 among bulk substances that may present significant safety risks in compounding.
The 2022 pharmacokinetic study measured BPC-157 in rats after intravenous and subcutaneous administration and described rapid exposure and tissue distribution in that animal model. It is a useful primary source for preclinical pharmacokinetics. It does not establish human half-life, human bioavailability, a clinically effective dose, a treatment schedule, or long-term human safety.
| Question | Best-supported answer | Evidence limit |
|---|---|---|
| What is the human half-life? | Unknown | No suitable published human PK study identified |
| What does ~15 minutes describe? | A rat-study plasma estimate after subcutaneous administration | Species and study-design limits apply |
| Does short plasma presence prove days of human effects? | No | Human pharmacodynamic duration is not established |
| Is BPC-157 FDA approved? | No approved product identified | FDA also flags potential compounding safety risks |
A biological response can outlast plasma exposure in some systems, but that general pharmacology principle does not prove a specific 24- to 72-hour human BPC-157 effect window. Claims about durable repair signaling, systemic outcomes, or an optimal schedule require direct evidence. Where that evidence is absent, the correct answer is unknown.
A tracker can preserve a research-context event, route, timestamp, unit, source, and notes. It cannot validate a product's identity, safety, efficacy, dose, or human pharmacokinetics. Model outputs based on the rat value must be labeled as nonhuman estimates.
| Parameter | Value | Source |
|---|---|---|
| Plasma Half-Life (SC, rat) | ~15 minutes | Xu et al. 2022 [1] |
| Plasma Half-Life (IV, animal) | ~4–5 minutes (estimated) | Animal PK data [1] |
| Time to Peak (Tmax) — SC | ~15–30 minutes (animal) | Xu et al. 2022 [1] |
| Route(s) of Administration | SC injection, IM injection, Oral | — |
| Human biological effect duration | Unknown | No suitable human evidence establishes a duration |
| Full Plasma Clearance (5 half-lives) | ~75 minutes (animal estimate) | Calculated |
| Human dose or schedule | Not established | No FDA-approved instructions or suitable human PK basis |
| Data Quality | Animal Study — No published human PK data exists as of May 2026 | — |
BPC-157's plasma half-life of approximately 15 minutes is derived from a 2022 rat pharmacokinetic study by Xu et al. (PMC9794587)[1], which characterized subcutaneous absorption, estimated plasma-remaining curves, and tissue distribution in animal models. This is the primary peer-reviewed pharmacokinetic data set for BPC-157. No equivalent study has been conducted in humans, and no human PK data has been published in peer-reviewed literature as of May 2026.
The peptide's rapid plasma clearance is a direct consequence of its molecular structure: BPC-157 is an unmodified 15-amino-acid sequence with no albumin-binding modifications, no PEGylation, and no half-life extension technology. These structural features make it susceptible to rapid proteolytic degradation by circulating and tissue-bound peptidases, as well as renal filtration given its small molecular weight.
Plasma half-life is measured by tracking compound concentration in blood samples over time following administration. In the Xu et al. 2022 study[1], rats received subcutaneous BPC-157 injections, and serial blood samples were collected to construct a plasma concentration-time curve. The time required for plasma concentration to fall by 50% — the half-life — was approximately 15 minutes for the subcutaneous route.
For intravenous administration in animal models, clearance is estimated to be faster (approximately 4–5 minutes), as the compound enters systemic circulation directly without the absorption phase associated with subcutaneous injection. These estimates are consistent with the compound's structural properties but have not been independently confirmed in prospective human studies.
This is the most clinically and practically important concept in BPC-157 pharmacology, and it is widely misunderstood. BPC-157 has three entirely distinct pharmacological timescales, each measuring something different:
Layer 1 — Plasma Half-Life (~15 minutes, animal data): This measures how quickly the intact BPC-157 molecule disappears from the bloodstream. After approximately 75 minutes (5 half-lives), less than 3% of the original dose remains in plasma. This is a pharmacokinetic measurement of molecular presence, not of biological activity. It tells you when the peptide has left the blood — not when it stops working[1].
Layer 2 — Detection: A universal detection window is not established here. Standard panels and specialized anti-doping methods differ, and athletes should consult the current rules and testing authority.
Layer 3 — Human biological effect duration: Unknown. Preclinical signaling observations do not establish a 24- to 72-hour human effect window.
Based on the animal pharmacokinetic data from Xu et al. 2022[1], plasma clearance of BPC-157 following subcutaneous injection follows predictable first-order kinetics with an approximately 15-minute half-life:
| Half-Lives Elapsed | Time Post-Injection | % Remaining in Plasma |
|---|---|---|
| 1 | ~15 minutes | 50% |
| 2 | ~30 minutes | 25% |
| 3 | ~45 minutes | 12.5% |
| 4 | ~60 minutes | 6.25% |
| 5 (clinical clearance threshold) | ~75 minutes | ~3% |
Plasma clearance and biological effect duration are not the same measurement. BPC-157 reaches clinical plasma clearance (less than 3% of original concentration) within approximately 75 minutes of subcutaneous injection in rat models. However, the downstream signaling cascades activated by BPC-157 — VEGFR2 phosphorylation, Akt-eNOS pathway activation, ERK1/2 signaling, and FAK-paxillin cytoskeletal remodeling — continue to operate for hours to days after the peptide has left circulation[1]. This is the pharmacokinetic/pharmacodynamic disconnect that makes BPC-157 unique among repair peptides and explains why once-daily administration is standard despite the short plasma half-life.
A short plasma half-life in rats does not establish a human dose, frequency, or biological-effect window. Community protocols are not a substitute for human pharmacokinetic, efficacy, or safety evidence.
This mechanism is fundamentally different from drugs that require continuous receptor occupancy — such as many enzyme inhibitors or receptor antagonists — where plasma concentration directly determines magnitude of effect. BPC-157 operates more like a growth factor: brief engagement with its receptor triggers a prolonged downstream transcriptional and structural response.
BPC-157 is occasionally administered orally, particularly in research focused on gastrointestinal conditions including inflammatory bowel disease, gastric ulceration, and gut-brain axis modulation. Oral peptide administration typically raises concerns about enzymatic degradation in the gastrointestinal tract before systemic absorption, which would be expected to substantially reduce bioavailability for most peptides.
BPC-157 appears to have some resistance to gastric acid degradation in animal studies, which is one mechanistic rationale for exploring oral administration — particularly for locally acting effects in the gastrointestinal tract where systemic absorption may not be necessary for efficacy. However, no published human pharmacokinetic study has characterized oral bioavailability for BPC-157, and systemic bioavailability via oral route in humans remains unknown. For effects requiring systemic distribution (tendon repair, systemic angiogenesis), subcutaneous or intramuscular injection is the preferred route in research protocols.
| Compound | Plasma Half-Life | Data Source | Data Quality |
|---|---|---|---|
| BPC-157 | ~15 min (SC, rat) | Xu et al. 2022 [1] | Animal Study |
| TB-500 | Not formally published | — | Inferred — no published PK study |
| GHK-Cu (topical) | Minutes (estimated) | Structural analog data | Inferred |
| KPV | <30 min (estimated) | Animal data | Animal Study |
| Route | Half-Life | Bioavailability | Tmax | Notes |
|---|---|---|---|---|
| Subcutaneous | ~15 min (rat) | Unknown in humans | ~15–30 min (animal) | Rat PK route; not an approved human use |
| Intramuscular | No published data | No published data | No published data | Human PK unknown |
| Intravenous | ~4–5 min (estimated) | 100% | Minutes | Reference route; rapid clearance |
| Oral | No published data | Potentially low (peptide degradation risk) | Unknown | Explored in GI repair research; some gastric acid resistance in animals |
A universal BPC-157 detection window is unknown. Routine workplace panels and specialized anti-doping assays are different systems. Competitive athletes should consult the current prohibited list and their testing authority rather than relying on a generalized time estimate.
The rat study supports rapid plasma clearance in that model. Mechanistic publications discuss possible signaling pathways, but those observations do not establish a human clinical effect, effect duration, or treatment schedule.
The correct evidence boundary is simple: animal pharmacokinetics can inform a preclinical model; it cannot be converted into an exact human pharmacokinetic or pharmacodynamic claim.
Preserve a timestamped research-context record while keeping all nonhuman model assumptions explicit.
Download on App StoreA clearly labeled nonhuman estimate based on recorded timing and the selected model. Free iOS app. Core protocol records stored on-device.
Download on App StoreKeep injection, site, vial, and observation records together while preserving the unknown human half-life.
Open tracker guide